

1-1 By: Lucio, et al. S.B. No. 553
1-2 (In the Senate - Filed January 27, 2009; February 23, 2009,
1-3 read first time and referred to Committee on Health and Human
1-4 Services; May 13, 2009, reported adversely, with favorable
1-5 Committee Substitute by the following vote: Yeas 6, Nays 3;
1-6 May 13, 2009, sent to printer.)

1-7 COMMITTEE SUBSTITUTE FOR S.B. No. 553 By: Deuell

1-8 A BILL TO BE ENTITLED
1-9 AN ACT

1-10 relating to the disclosure of certain economic benefits provided to
1-11 health professionals in the marketing of prescription drugs,
1-12 medical devices, and medical supplies; providing penalties.

1-13 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

1-14 SECTION 1. Chapter 431, Health and Safety Code, is amended
1-15 by adding Subchapter O to read as follows:

1-16 SUBCHAPTER O. REPORTING REQUIREMENTS RELATED TO MARKETING OF
1-17 PRESCRIPTION DRUGS, MEDICAL DEVICES, AND MEDICAL SUPPLIES

1-18 Sec. 431.451. DEFINITIONS. In this subchapter:

1-19 (1) "Bona fide clinical trial" means any study
1-20 assessing the safety or efficacy of:

1-21 (A) drugs administered alone or in combination
1-22 with other drugs or other therapies or assessing the relative
1-23 safety or efficacy of drugs in comparison with other drugs or other
1-24 therapies; or

1-25 (B) a medical device.

1-26 (2) "Distributor" means a person who furthers the
1-27 marketing of a prescription drug, medical device, or medical supply
1-28 from the original place of manufacture to the person who makes final
1-29 delivery or sale to the ultimate consumer or user.

1-30 (3) "Gift" means a payment, food, entertainment,
1-31 travel, honorarium, subscription, advance, service, product
1-32 sample, or anything of value, unless consideration of equal or
1-33 greater value is received, and includes anything of value provided
1-34 for less than market value.

1-35 (4) "Health professional" means:

1-36 (A) a physician;

1-37 (B) a physician medical practice; and

1-38 (C) a physician group practice.

1-39 (5) "Manufacturer" means a person who manufactures,
1-40 fabricates, distributes, or repackages a prescription drug,
1-41 medical device, or medical supply.

1-42 (6) "Marketer" means a person who, while employed by
1-43 or under contract to represent a manufacturer, repackager, or
1-44 retailer, engages in detailing, promotional activity, or other
1-45 marketing of a prescription drug, medical device, or medical supply
1-46 in this state to a physician, hospital, nursing home, pharmacist,
1-47 health benefit plan administrator, or other health professional.

1-48 (7) "Medical device" or "device" means an instrument,
1-49 apparatus, implement, machine, contrivance, implant, in vitro
1-50 reagent, or other similar or related article, including any
1-51 component, part, or accessory, which is:

1-52 (A) recognized in the official National
1-53 Formulary or the United States Pharmacopia, or any supplement
1-54 thereto;

1-55 (B) intended for use in the diagnosis of disease
1-56 or other conditions, or in the cure, mitigation, treatment, or
1-57 prevention of disease in humans; or

1-58 (C) intended to affect the structure or any
1-59 function of the human body, and which does not achieve its primary
1-60 intended purposes through chemical action within or on the human
1-61 body and which is not dependent upon being metabolized for the
1-62 achievement of its primary intended purposes.

1-63 (8) "Prescription drug" has the meaning assigned by 21

2-1 C.F.R. Section 203.3.
 2-2 (9) "Repackage" means repackaging or otherwise
 2-3 changing the container, wrapper, or labeling of a prescription
 2-4 drug, medical device, or medical supply to further the distribution
 2-5 of the drug, device, or supply. The term does not include
 2-6 repackaging by a pharmacist to dispense a drug, device, or supply to
 2-7 a patient.
 2-8 (10) "Repackager" means a person who engages in
 2-9 repackaging.
 2-10 (11) "Retailer" means a person who is engaged in the
 2-11 business of buying for resale, selling, or exchanging a medical
 2-12 device or medical supply or offering a device or supply for sale,
 2-13 exchange, or lease-purchase to a consumer or user.
 2-14 Sec. 431.452. APPLICABILITY OF SUBCHAPTER. This subchapter
 2-15 applies only to a manufacturer, repackager, or retailer that
 2-16 exceeds \$30 million in annual gross revenue and that manufactures,
 2-17 markets, sells, distributes, produces, prepares, compounds,
 2-18 converts, or processes a medical device, medical supply, or
 2-19 prescription drug for which payment is available through the
 2-20 medical assistance program under Chapter 32, Human Resources Code,
 2-21 or under Title XVIII, XIX, or XXI of the Social Security Act (42
 2-22 U.S.C. Sections 1395 et seq. and 1397aa et seq.).
 2-23 Sec. 431.453. ANNUAL DISCLOSURE OF CERTAIN ECONOMIC
 2-24 BENEFITS. (a) Not later than March 31 of each year, a manufacturer
 2-25 or repackager that sells, repackages, or distributes prescription
 2-26 drugs, medical devices, or medical supplies in this state, and a
 2-27 retailer that sells medical devices or medical supplies in this
 2-28 state, shall submit to the department a report that discloses any
 2-29 gift, fee, payment, subsidy, or other economic benefit given, paid,
 2-30 or provided by the manufacturer, repackager, or retailer to a
 2-31 physician, physician's office, hospital, nursing home, pharmacist,
 2-32 health benefit plan administrator, or other health professional in
 2-33 connection with detailing, promotional, or marketing activities of
 2-34 the manufacturer, repackager, or retailer, directly or through a
 2-35 marketer.
 2-36 (b) A report required under Subsection (a) must cover the
 2-37 preceding calendar year and must be submitted on a form, including
 2-38 any electronic form, prescribed by the department. In connection
 2-39 with each gift, fee, payment, subsidy, or other economic benefit
 2-40 required to be disclosed under this subchapter, the report must
 2-41 include:
 2-42 (1) the name and business address of each recipient of
 2-43 the benefit;
 2-44 (2) the value of each benefit;
 2-45 (3) the date of payment or transfer of each benefit;
 2-46 (4) a categorized description of the form of each
 2-47 benefit, including:
 2-48 (A) cash or cash equivalent;
 2-49 (B) an in-kind item or service;
 2-50 (C) an ownership interest or other return on
 2-51 investment, including securities, stock options, dividends, or
 2-52 profit-sharing arrangement; and
 2-53 (D) any other category the commissioner deems
 2-54 appropriate;
 2-55 (5) a categorized description of the nature of each
 2-56 benefit, including:
 2-57 (A) a consulting fee;
 2-58 (B) compensation for a service other than
 2-59 consulting;
 2-60 (C) honoraria;
 2-61 (D) a gift;
 2-62 (E) entertainment;
 2-63 (F) food;
 2-64 (G) travel;
 2-65 (H) education;
 2-66 (I) research;
 2-67 (J) a charitable contribution;
 2-68 (K) a royalty or license;
 2-69 (L) current or prospective ownership of an

3-1 investment interest;
 3-2 (M) compensation for serving as faculty or as a
 3-3 speaker for a continuing medical education program;
 3-4 (N) a grant; and
 3-5 (O) any other category the commissioner
 3-6 determines appropriate;
 3-7 (6) if the payment or transfer of the benefit is
 3-8 related to marketing, education, or research specific to a
 3-9 particular prescription drug, medical device, or medical supply the
 3-10 name of the drug, device, or supply; and
 3-11 (7) any other category of information regarding the
 3-12 payment or transfer of a benefit the commissioner determines
 3-13 appropriate.
 3-14 (c) Not later than May 1 of each year, the department shall
 3-15 make all reports submitted under this section on or before March 31
 3-16 available on the department's Internet website. The department
 3-17 shall make reports submitted under this section after March 31
 3-18 available on the department's Internet website as soon as
 3-19 practicable.
 3-20 (d) The reporting requirements described by Subsections (a)
 3-21 and (b) do not apply in an area of the state designated in an
 3-22 executive order or a proclamation by the governor under Chapter
 3-23 418, Government Code, during the 30-day period after the executive
 3-24 order or proclamation is issued.
 3-25 Sec. 431.454. EXEMPTIONS. (a) The following economic
 3-26 benefits are exempt from disclosure under Section 431.453:
 3-27 (1) a gift, fee, payment, subsidy, or other economic
 3-28 benefit with a fair market value that is less than \$50;
 3-29 (2) free samples of prescription drugs intended for
 3-30 distribution to patients;
 3-31 (3) any prescription drug rebate or discount;
 3-32 (4) payment of reasonable compensation and
 3-33 reimbursement of expenses in connection with a bona fide clinical
 3-34 trial;
 3-35 (5) a scholarship or other support for a medical
 3-36 student, resident, or fellow to attend a bona fide educational,
 3-37 scientific, or policy-making conference of an established
 3-38 professional association if the recipient of the scholarship or
 3-39 other support is selected by the association;
 3-40 (6) a grant or other support for the development,
 3-41 production, or presentation of a bona fide educational, scientific,
 3-42 or policy-making program or conference of an established
 3-43 professional association if the professional association
 3-44 independently selects, develops, produces, or presents the
 3-45 educational, scientific, or policy-making program or conference;
 3-46 (7) educational materials that directly benefit
 3-47 patients or are intended for patient use;
 3-48 (8) in-kind items used for the provision of charity
 3-49 care;
 3-50 (9) any transfer or payment of a benefit to treat a
 3-51 health condition of an individual described by Section 431.453(a),
 3-52 where the individual is a patient and is not acting in a
 3-53 professional capacity;
 3-54 (10) a dividend or other profit distribution from, or
 3-55 an ownership or investment interest in, a mutual fund or
 3-56 publically-traded security;
 3-57 (11) the loan of a device for a short-term trial
 3-58 period, not to exceed 90 days, to permit evaluation of the device by
 3-59 the recipient; and
 3-60 (12) items or services provided under a contractual
 3-61 warranty, including the replacement of a device, where the terms
 3-62 for the warranty are set forth in the purchase or lease agreement
 3-63 for the covered device.
 3-64 (b) Notwithstanding Subsection (a)(1), any aggregate
 3-65 payment or transfer of a benefit to a single recipient during an
 3-66 annual reporting period that does not exceed \$100 is exempt under
 3-67 this section. Any value associated with free samples or with a
 3-68 dividend or other profit distribution may be excluded from the
 3-69 calculation of aggregate value.

4-1 Sec. 431.455. PENALTIES; INJUNCTION. (a) The
4-2 commissioner may, in accordance with the procedures applicable to
4-3 administrative penalties assessed under Subchapter C, assess an
4-4 administrative penalty against a person who fails to file a report
4-5 required under this subchapter.

4-6 (b) The attorney general may bring an action:
4-7 (1) for injunctive relief to compel a person to file a
4-8 report required under this subchapter; and

4-9 (2) to impose a civil penalty of not more than \$10,000
4-10 for a failure to file a report required under this subchapter.

4-11 (c) Each failure to file a report required under this
4-12 subchapter constitutes a separate violation.

4-13 (d) The court may award to the attorney general reasonable
4-14 court costs and attorney's fees in connection with an action
4-15 brought under Subsection (b).

4-16 Sec. 431.456. PUBLIC RECORDS. The information required to
4-17 be submitted to the department under this subchapter and the data
4-18 and reports compiled by the department based on that information
4-19 are public records under Chapter 552, Government Code.
4-20 Notwithstanding any other provision of law, the identity of any
4-21 recipient of a gift, fee, payment, subsidy, or other economic
4-22 benefit required to be reported under this subchapter does not
4-23 constitute confidential information or a trade secret.

4-24 Sec. 431.457. SUSPENSION OF STATE REPORTING REQUIREMENTS.
4-25 If a federal law provides for the disclosure of gifts to health
4-26 professionals by manufacturers, repackagers, or retailers to whom
4-27 this subchapter applies and the commissioner determines that the
4-28 federal law substantially meets the purposes of provisions of this
4-29 subchapter, the department shall suspend the application of the
4-30 state reporting requirements imposed under those provisions.

4-31 SECTION 2. (a) Not later than March 31, 2011, the
4-32 executive commissioner of the Health and Human Services Commission
4-33 shall adopt the rules and procedures necessary to implement
4-34 Subchapter O, Chapter 431, Health and Safety Code, as added by this
4-35 Act, including rules defining bona fide programs and conferences
4-36 under Subdivisions (5) and (6), Section 431.454, Health and Safety
4-37 Code, as added by this Act.

4-38 (b) Not later than March 31, 2011, the Department of State
4-39 Health Services shall develop the form required by Section 431.453,
4-40 Health and Safety Code, as added by this Act.

4-41 (c) Notwithstanding Section 431.453, Health and Safety
4-42 Code, as added by this Act, a manufacturer, repackager, or retailer
4-43 of prescription drugs, medical devices, or medical supplies is not
4-44 required to submit the report required by that section before
4-45 March 31, 2012.

4-46 SECTION 3. This Act takes effect January 1, 2011.

4-47 * * * * *